カテゴリー： QYResearch, 世界, 医療/バイオ

組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のグローバル市場2023年：バイアル、プレフィルド

◆英語タイトル：Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Research Report 2023
	◆商品コード：QYR23MA8882 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2023年3月 ◆ページ数：112 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD2,900 ⇒換算￥435,000	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD4,350 ⇒換算￥652,500	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD5,800 ⇒換算￥870,000	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場について調査・分析し、世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（バイアル、プレフィルド）、用途別セグメント分析（骨髄抑制化学療法、白血病化学療法、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Abbott、Amgen、Arven Pharmaceuticals、Biocon、Cadila Pharmaceuticals、Dr.Reddy's Laboratories、Emcure Pharmaceuticals、Intas Pharmaceuticals、Kyowa Kirin、Novartis、Pfizer、Reliance Life Sciences、Harbin Pharmaceutical、North China Pharmaceutical、Jiuyuan Gene、Kexing Biopharm、Qilu Pharmaceutical、Quangang Pharmaceutical、Sunway Biotech、SL Pharmaceutical、Four Rings Bio-Pharmaceutical、Amoytop、Wuzhong Pharmaceuticalなどが含まれています。世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模を推定する際に考慮しました。

・組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場の概要
- 製品の定義
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のタイプ別セグメント
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模：タイプ別分析（バイアル、プレフィルド）
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別セグメント
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模：用途別分析（骨髄抑制化学療法、白血病化学療法、その他）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模予測（2018年-2029年）
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場の競争状況およびトレンド

・組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の地域別市場規模
- 北米の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- アメリカの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- ヨーロッパの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- アジア太平洋の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 中国の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 日本の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 韓国の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- インドの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- オーストラリアの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 中南米の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）
- 中東・アフリカの組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場規模（2018年-2029年）

・タイプ別セグメント：バイアル、プレフィルド
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のタイプ別販売量（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のタイプ別売上（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のタイプ別価格

・用途別セグメント：骨髄抑制化学療法、白血病化学療法、その他
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別販売量（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別売上（2018年-2023年）
- 世界の組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Abbott、Amgen、Arven Pharmaceuticals、Biocon、Cadila Pharmaceuticals、Dr.Reddy's Laboratories、Emcure Pharmaceuticals、Intas Pharmaceuticals、Kyowa Kirin、Novartis、Pfizer、Reliance Life Sciences、Harbin Pharmaceutical、North China Pharmaceutical、Jiuyuan Gene、Kexing Biopharm、Qilu Pharmaceutical、Quangang Pharmaceutical、Sunway Biotech、SL Pharmaceutical、Four Rings Bio-Pharmaceutical、Amoytop、Wuzhong Pharmaceutical

・産業チェーンと販売チャネルの分析
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）産業チェーン分析
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の主要原材料
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の販売チャネル
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のディストリビューター
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の主要顧客

・組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場ダイナミクス
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）の業界動向
- 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) include Abbott, Amgen, Arven Pharmaceuticals, Biocon, Cadila Pharmaceuticals, Dr.Reddy’s Laboratories, Emcure Pharmaceuticals, Intas Pharmaceuticals and Kyowa Kirin, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF).
The Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size, estimations, and forecasts are provided in terms of sales volume (K L) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Abbott
Amgen
Arven Pharmaceuticals
Biocon
Cadila Pharmaceuticals
Dr.Reddy’s Laboratories
Emcure Pharmaceuticals
Intas Pharmaceuticals
Kyowa Kirin
Novartis
Pfizer
Reliance Life Sciences
Harbin Pharmaceutical
North China Pharmaceutical
Jiuyuan Gene
Kexing Biopharm
Qilu Pharmaceutical
Quangang Pharmaceutical
Sunway Biotech
SL Pharmaceutical
Four Rings Bio-Pharmaceutical
Amoytop
Wuzhong Pharmaceutical
Segment by Type
Vials
Prefilled
Segment by Application
Myelosuppressive Chemotherapy
Leukemia Chemotherapy
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Overview
1.1 Product Overview and Scope of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
1.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Type
1.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value Comparison by Type (2023-2029)
1.2.2 Vials
1.2.3 Prefilled
1.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Application
1.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Value by Application: (2023-2029)
1.3.2 Myelosuppressive Chemotherapy
1.3.3 Leukemia Chemotherapy
1.3.4 Others
1.4 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue 2018-2029
1.4.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales 2018-2029
1.4.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Competition by Manufacturers
2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), Product Type & Application
2.7 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Competitive Situation and Trends
2.7.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Players Market Share by Revenue
2.7.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Retrospective Market Scenario by Region
3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region: 2018-2029
3.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region: 2018-2023
3.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region: 2024-2029
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region: 2018-2029
3.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region: 2018-2023
3.3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region: 2024-2029
3.4 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.4.1 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.4.3 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.5.3 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2029)
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2018-2023)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Type (2024-2029)
4.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Type (2018-2029)
4.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Type (2018-2023)
4.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Type (2024-2029)
4.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2029)
5.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2018-2023)
5.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Application (2024-2029)
5.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Application (2018-2029)
5.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Application (2018-2023)
5.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Application (2024-2029)
5.2.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Abbott
6.1.1 Abbott Corporation Information
6.1.2 Abbott Description and Business Overview
6.1.3 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.1.5 Abbott Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Arven Pharmaceuticals
6.3.1 Arven Pharmaceuticals Corporation Information
6.3.2 Arven Pharmaceuticals Description and Business Overview
6.3.3 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.3.5 Arven Pharmaceuticals Recent Developments/Updates
6.4 Biocon
6.4.1 Biocon Corporation Information
6.4.2 Biocon Description and Business Overview
6.4.3 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.4.5 Biocon Recent Developments/Updates
6.5 Cadila Pharmaceuticals
6.5.1 Cadila Pharmaceuticals Corporation Information
6.5.2 Cadila Pharmaceuticals Description and Business Overview
6.5.3 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.5.5 Cadila Pharmaceuticals Recent Developments/Updates
6.6 Dr.Reddy’s Laboratories
6.6.1 Dr.Reddy’s Laboratories Corporation Information
6.6.2 Dr.Reddy’s Laboratories Description and Business Overview
6.6.3 Dr.Reddy’s Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Dr.Reddy’s Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.6.5 Dr.Reddy’s Laboratories Recent Developments/Updates
6.7 Emcure Pharmaceuticals
6.6.1 Emcure Pharmaceuticals Corporation Information
6.6.2 Emcure Pharmaceuticals Description and Business Overview
6.6.3 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.7.5 Emcure Pharmaceuticals Recent Developments/Updates
6.8 Intas Pharmaceuticals
6.8.1 Intas Pharmaceuticals Corporation Information
6.8.2 Intas Pharmaceuticals Description and Business Overview
6.8.3 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.8.5 Intas Pharmaceuticals Recent Developments/Updates
6.9 Kyowa Kirin
6.9.1 Kyowa Kirin Corporation Information
6.9.2 Kyowa Kirin Description and Business Overview
6.9.3 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.9.5 Kyowa Kirin Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Pfizer
6.11.1 Pfizer Corporation Information
6.11.2 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.11.3 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.11.5 Pfizer Recent Developments/Updates
6.12 Reliance Life Sciences
6.12.1 Reliance Life Sciences Corporation Information
6.12.2 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.12.3 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.12.5 Reliance Life Sciences Recent Developments/Updates
6.13 Harbin Pharmaceutical
6.13.1 Harbin Pharmaceutical Corporation Information
6.13.2 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.13.3 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.13.5 Harbin Pharmaceutical Recent Developments/Updates
6.14 North China Pharmaceutical
6.14.1 North China Pharmaceutical Corporation Information
6.14.2 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.14.3 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.14.4 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.14.5 North China Pharmaceutical Recent Developments/Updates
6.15 Jiuyuan Gene
6.15.1 Jiuyuan Gene Corporation Information
6.15.2 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.15.3 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.15.5 Jiuyuan Gene Recent Developments/Updates
6.16 Kexing Biopharm
6.16.1 Kexing Biopharm Corporation Information
6.16.2 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.16.3 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.16.5 Kexing Biopharm Recent Developments/Updates
6.17 Qilu Pharmaceutical
6.17.1 Qilu Pharmaceutical Corporation Information
6.17.2 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.17.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.17.5 Qilu Pharmaceutical Recent Developments/Updates
6.18 Quangang Pharmaceutical
6.18.1 Quangang Pharmaceutical Corporation Information
6.18.2 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.18.3 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.18.5 Quangang Pharmaceutical Recent Developments/Updates
6.19 Sunway Biotech
6.19.1 Sunway Biotech Corporation Information
6.19.2 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.19.3 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.19.5 Sunway Biotech Recent Developments/Updates
6.20 SL Pharmaceutical
6.20.1 SL Pharmaceutical Corporation Information
6.20.2 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.20.3 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.20.4 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.20.5 SL Pharmaceutical Recent Developments/Updates
6.21 Four Rings Bio-Pharmaceutical
6.21.1 Four Rings Bio-Pharmaceutical Corporation Information
6.21.2 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.21.3 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.21.5 Four Rings Bio-Pharmaceutical Recent Developments/Updates
6.22 Amoytop
6.22.1 Amoytop Corporation Information
6.22.2 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.22.3 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.22.5 Amoytop Recent Developments/Updates
6.23 Wuzhong Pharmaceutical
6.23.1 Wuzhong Pharmaceutical Corporation Information
6.23.2 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
6.23.3 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
6.23.5 Wuzhong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Chain Analysis
7.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Production Mode & Process
7.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales and Marketing
7.4.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Channels
7.4.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Distributors
7.5 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Customers
8 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Dynamics
8.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Trends
8.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Drivers
8.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Challenges
8.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のグローバル市場2023年：バイアル、プレフィルド(Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

組換えヒト顆粒球コロニー刺激因子注射（rhG-CSF）のグローバル市場2023年：バイアル、プレフィルド

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp